Lung Cancer

The FDA has accepted a supplemental biologics license application for atezolizumab, carboplatin, and nab-paclitaxel as a first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer.

Lara Kujtan, MD, sheds light on how to navigate the complex paradigm of oncogene-driven non–small cell lung cancer and stressed the importance of patient preferences when deciding on optimal treatment approaches.

Janakiraman Subramanian, MD, medical oncologist, director of Thoracic Oncology, Center for Precision Medicine, Saint Luke’s Cancer Institute, discusses ongoing trials evaluating the use of immunotherapy in patients with nonsquamous non–small cell lung cancer (NSCLC).

J. Russell Davis, MD, clinical professor, University of Missouri-Kansas City School of Medicine, thoracic surgeon, Saint Luke's Hospital, discusses the benefits of robotics in thoracic surgery.

Kwok-Kin Wong, MD, PhD, Anne Murnick Cogan and David H. Cogan Professor of Oncology, Department of Medicine, and director of the Division of Hematology and Medical Oncology at NYU Langone’s Perlmutter Cancer Center, discusses the current landscape of non–small cell lung cancer (NSCLC).

Kwok-Kin Wong, MD, PhD, discusses updates in non–small cell lung cancer and the importance of enrolling patients in clinical trials to further progress the field.

Joshua K. Sabari, MD, assistant professor of medicine, NYU Langone's Perlmutter Cancer Center, discusses biomarkers of immunotherapy response in non–small cell lung cancer.

Elaine Shum, MD, discusses the rapidly evolving treatment options for patients with oncogene-driven non–small cell lung cancer.

Study results demonstrate that men and women differ in their immunological responses to foreign and self-antigens.